Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
SRPT on Nasdaq
Shares outstanding
105,632,895
Price per share
$21.52
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
86,806,847
Total reported value
$1,674,704,335
% of total 13F portfolios
0%
Share change
+3,417,529
Value change
+$92,781,986
Number of holders
310
Price from insider filings
$21.52
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 11% $190,912,690 10,641,733 The Vanguard Group 29 Aug 2025
STATE STREET CORP 5.4% $102,225,558 5,304,907 STATE STREET CORPORATION 30 Sep 2025
D. E. SHAW & CO, L.P. 1.9% -64% $38,675,372 -$58,829,132 2,007,025 -60% D. E. Shaw & Co., L.P. 30 Sep 2025
Capital International Investors 0.5% -98% $9,523,733 -$152,120,639 524,146 -94% Capital International Investors 30 Jun 2025

As of 30 Sep 2025, 310 institutional investors reported holding 86,806,847 shares of Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT). This represents 82% of the company’s total 105,632,895 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT) together control 61% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 12% 13,199,845 +9% 0% $254,361,023
VANGUARD GROUP INC 10% 10,817,446 +18% 0% $208,452,185
STATE STREET CORP 5% 5,304,907 +13% 0% $102,225,558
Erste Asset Management GmbH 2.5% 2,685,945 +66% 0.49% $50,588,160
RENAISSANCE TECHNOLOGIES LLC 2.5% 2,650,178 +324% 0.07% $51,068,930
TWO SIGMA INVESTMENTS, LP 2% 2,137,764 -1.1% 0.06% $41,194,712
D. E. Shaw & Co., Inc. 1.9% 2,007,025 -55% 0.03% $38,675,372
UBS Group AG 1.9% 1,990,508 +297% 0.01% $38,357,088
Aberdeen Group plc 1.9% 1,982,764 +60% 0.06% $38,207,862
TWO SIGMA ADVISERS, LP 1.9% 1,958,034 -1.4% 0.08% $37,731,315
MORGAN STANLEY 1.8% 1,948,358 +31% 0% $37,544,863
FIRST TRUST ADVISORS LP 1.8% 1,939,781 +209% 0.03% $37,379,579
BNP PARIBAS FINANCIAL MARKETS 1.7% 1,781,348 0% 0.03% $34,326,576
Connor, Clark & Lunn Investment Management Ltd. 1.7% 1,745,051 +184% 0.11% $33,627,133
GEODE CAPITAL MANAGEMENT, LLC 1.6% 1,721,124 -8.3% 0% $33,172,867
AQR CAPITAL MANAGEMENT LLC 1.3% 1,405,675 +1016% 0.02% $26,398,577
T. Rowe Price Investment Management, Inc. 1.3% 1,366,690 +188% 0.02% $26,337,000
VOLORIDGE INVESTMENT MANAGEMENT, LLC 1.2% 1,308,738 -11% 0.08% $25,219,381
FEDERATED HERMES, INC. 1.2% 1,308,691 +0.04% 0.04% $25,218,476
CITIGROUP INC 0.96% 1,018,922 +384% 0.01% $19,634,627
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.94% 990,866 +450% 0.03% $19,093,988
683 Capital Management, LLC 0.94% 990,000 +47% 1.7% $19,077,300
Amundi 0.92% 969,826 +378% 0.01% $22,558,153
Invesco Ltd. 0.79% 832,638 +242% 0% $16,044,935
BRAIDWELL LP 0.79% 832,100 0.48% $16,034,567

Institutional Holders of Sarepta Therapeutics, Inc. - Common Stock, $0.0001 par value per share (SRPT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 396,003 $8,625,454 -$5,789,312 $21.52 15
2025 Q3 86,806,847 $1,674,704,335 +$92,781,986 $19.27 310
2025 Q2 82,768,888 $1,414,059,003 -$616,173,124 $17.10 354
2025 Q1 85,664,154 $5,483,381,207 -$371,527,547 $63.82 419
2024 Q4 87,843,903 $10,682,091,570 +$115,071,840 $121.59 459
2024 Q3 86,796,388 $10,834,992,283 -$451,898,219 $124.89 451
2024 Q2 88,782,224 $14,026,709,174 +$922,747,140 $158.00 479
2024 Q1 83,236,471 $10,771,794,424 +$210,287,311 $129.46 408
2023 Q4 81,574,475 $7,866,654,991 -$295,015,527 $96.43 386
2023 Q3 83,265,476 $10,092,124,857 +$213,088,130 $121.22 390
2023 Q2 81,723,093 $9,359,752,457 +$62,411,602 $114.52 399
2023 Q1 81,211,200 $11,191,507,838 +$325,102,660 $137.83 422
2022 Q4 78,931,000 $10,227,280,074 +$92,872,677 $129.58 405
2022 Q3 78,254,620 $8,650,122,111 +$568,958,858 $110.54 364
2022 Q2 73,313,897 $5,496,320,989 +$35,960,887 $74.96 312
2022 Q1 73,015,967 $5,705,221,328 +$56,363,206 $78.12 314
2021 Q4 71,894,248 $6,474,592,585 +$536,221,296 $90.05 326
2021 Q3 65,753,485 $6,079,879,477 +$130,063,243 $92.48 297
2021 Q2 64,801,548 $5,037,256,042 -$83,636,915 $77.74 315
2021 Q1 66,263,834 $4,936,320,529 -$714,137,111 $74.53 346
2020 Q4 70,628,202 $12,036,993,873 -$160,139,710 $170.49 435
2020 Q3 72,104,327 $10,123,672,605 -$335,637,260 $140.43 393
2020 Q2 73,863,151 $11,844,121,308 +$150,679,056 $160.34 397
2020 Q1 73,412,115 $7,179,418,082 -$46,251,906 $97.82 346
2019 Q4 73,511,794 $9,484,309,752 +$56,244,489 $129.04 379
2019 Q3 73,245,840 $5,516,516,594 -$252,303,319 $75.32 329
2019 Q2 71,710,913 $10,889,813,246 +$292,081,135 $151.95 359
2019 Q1 71,059,216 $8,477,596,090 +$290,725,751 $119.19 359
2018 Q4 68,661,818 $7,492,575,765 +$726,945,004 $109.13 325
2018 Q3 61,212,693 $9,884,755,828 +$245,516,894 $161.51 336
2018 Q2 59,953,943 $7,924,528,334 +$548,877,233 $132.18 311
2018 Q1 56,761,587 $4,203,831,314 +$181,642,965 $74.09 265
2017 Q4 55,206,092 $3,072,290,058 +$54,898,638 $55.64 246
2017 Q3 53,730,465 $2,441,631,878 +$525,830,388 $45.36 229
2017 Q2 42,713,217 $1,439,533,207 +$80,813,352 $33.71 186
2017 Q1 40,738,464 $1,205,704,254 +$221,363,966 $29.60 177
2016 Q4 39,367,759 $1,079,914,087 -$175,937,880 $27.43 175
2016 Q3 42,406,897 $2,603,203,193 +$578,983,777 $61.41 183
2016 Q2 34,630,592 $660,414,393 -$14,436,681 $19.07 142
2016 Q1 35,134,647 $685,755,808 +$88,658,017 $19.52 129
2015 Q4 28,532,796 $1,100,883,608 +$34,445,813 $38.58 146
2015 Q3 27,764,899 $891,509,724 +$36,642,722 $32.11 145
2015 Q2 26,667,019 $811,458,439 +$87,268,791 $30.43 127
2015 Q1 24,203,223 $321,208,632 -$7,502,400 $13.28 111
2014 Q4 24,718,769 $357,295,111 -$43,901,247 $14.47 118
2014 Q3 25,967,938 $547,925,873 -$18,480,997 $21.10 121
2014 Q2 26,655,127 $794,069,375 +$1,202,234 $29.79 126
2014 Q1 26,596,410 $639,243,096 -$12,446,044 $24.03 114